Global Statistics Representing Gene Therapy Cell Culture Media Market Scenario
Gene therapy is a modern treatment for correcting defective genes. In addition, various pharmaceutical industries are focused on developing treatments for monogenic diseases. Culture media is necessary for the cell cultures to grow and survive in their incubation environment, and to support the growth and maintenance of genes. Advantages of highly concentrated feeds and media are known to pharmaceutical and biotechnology, and companies focusing on gene therapy. Concentration allows for higher cell density and improved economics in the form of lower feed rates, higher volumetric productivity, and lower volumes of media in storage, which is further improving the efficiency of the culture media for gene therapy.
Global gene therapy cell culture media market was valued at USD 142.70 million in 2018, growing at a CAGR of 10.9% during the forecast period of 2019–2026.
Increasing research and development in gene therapy driving the growth of the market
Major players in the pharmaceutical and biotechnology sector are heavily investing in the manufacturing facilities for the development of gene therapy products. In 2019, Pfizer Inc., announced an investment of USD 500 million for expanding manufacturing facility to start experimenting on gene therapies. Additionally, in 2016, Bayer and ERS Genomics entered in Patent license agreement for Bayer to gain access to ‘ERS Genomics' CRISPR-Cas9 patents.
For a better understanding of the global gene therapy cell culture media market, we have segmented the market by type, and end user.
By type, the market is segmented into lysogeny broth, chemically defined media, serum-free media, specialty media, stem cell media, and custom media. Chemically defined media is accounting for the second largest market share and was valued at USD 45.23 million in 2018. Chemically defined media contains amino acid in fixed proportion for cell culture and is free from any animal-derived components. Mainly, it is used in the production of vaccines and for culturing human and animal cells. In 2016, the US FDA approved cell-based flu vaccine based on cell-grown CVVs.
Global gene therapy cell culture media market by Americas, Asia Pacific, Europe, and the Middle East and Africa.
North America is dominating the market and accounted for the highest share in the forecast period. Gene therapy is a booming field in North America with several approved products like ‘Luxturna’ developed by Spark Therapeutics, and ‘Zolgensma’ developed by ‘AveXis,’ to name a few. In addition, the US FDA has approved ‘Landmark AAV-Delivered Gene Therapy’ by Zolgensma to treat spinal muscular atrophy. Constant inflow of investments in research & development in gene therapy for the treatment of rare genetic diseases is likely to influence the Gene Therapy Cell Culture Media market in North America, positively. In April 2019, ‘Asklepios BioPharmaceutical (AskBio)’ bagged USD 235 million investment for the development in gene therapy
Europe is second leading region in the forecast period owing to higher healthcare spending. The growth can be attributed to increase in clinical trials for gene therapy. For instance, clinical trials increased by 37% in 2018 as compared to 2017, the Cell and Gene Therapy Catapult. In addition, several in-vivo exposure therapies are entering Phase III, which is driving the Gene Therapy Cell Culture Media market. Moreover, ongoing gene therapy research & development, and clinical trials are mainly sponsored by commercial and academic/non-profit sponsors. The trend for sponsorships changed upside down during 2013–2018; More than 70% of the sponsors were academic/non-profit during 2013-2015 and the number reduced to 59% and 57% in 2016 and 2017, respectively. In 2018, sponsorships from commercial entities increased to 66%, out of which only one-third were backed up by the U.K based organizations, rest were backed by companies outside the U.K.
Middle East & Africa is offering various lucrative opportunities for the market. The region homes very low number of players in gene therapy and inadequate research and development activities are restricting the growth of Gene Therapy Cell Culture Media market. However, the situation has improved a bit in the recent years as some of the major players in the pharmaceutical and biotechnology sector have started focusing on gene therapy and are looking forward to opportunities for establishing research & development centers in the Middle East & Africa.
Some of the prominent players in the market are Lonza, HiMedia, GE Healthcare, FUJIFILM Irvine Scientific, R&D Systems, Inc. (Bio-Techne), Thermo Fisher Scientific and Sartorius AG.
Gene Therapy Cell Culture Media Market Segmentation
By End User
Frequently Asked Questions (FAQs)